Active, not recruitingInterventionalPhase 4Last updated Aug 12, 2026

Daily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction

Efficacy of Daily 5-mg Tadalafil as Adjunctive Therapy Versus Monotherapy in Men With On-Demand PDE5 Inhibitor-Resistant Erectile Dysfunction: A Prospective Randomized Trial

Overview

ClinicalTrials.gov ID: NCT07753720
Lead Sponsor: Al-Azhar UniversityOTHER
Brief Summary: This randomized trial will compare daily tadalafil 5 mg as adjunct therapy versus monotherapy in men with on-demand PDE5 inhibitor-resistant erectile dysfunction. The study will evaluate changes in erectile function, treatment satisfaction, partner satisfaction, and safety over 12 weeks.
Study Type

Status

Overall Status: Active, not recruiting
Start Date: Aug 10, 2026Actual
Primary Completion Date: Jun 30, 2027Estimated
Completion Date: Jun 30, 2027Estimated

Study Record Dates

First Submitted: Jul 29, 2026
First Submitted that Met QC Criteria: Aug 6, 2026
First Posted: Aug 7, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 11, 2026
Last Update Posted: Aug 12, 2026Actual
Last Verified: Jul 2026

NCT07391579Recruiting

Daily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients

NCT07177326Not yet recruiting

Combination Therapy of Tadalafil 2.5mg Plus Sildenafil 25mg Versus Tadalafil 5 mg Monotherapy for Treatment of Erectile Dysfunction: A Randomized, Placebo-Controlled Double-Blinded Cross-Over Study

NCT00836693Completed

Effect of Tadalafil Once a Day in Men With Erectile Dysfunction

NCT01130532Completed

A Study in Erectile Dysfunction

NCT00381732Completed

A Study to Evaluate the Efficacy and Safety of 2.5mg and 5mg Tadalafil Given Once a Day to Men With Erectile Dysfunction

NCT00422734Completed

Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life